APOL1 and chronic kidney disease: The reduced in vivo tumorigenic potential of RCC G1 and G2 predicts that human carriers of these variants may be relatively protected from RCC and suggests that the high incidence of RCC in the black population is unrelated to the APOL1 RV for CKD.